Navigation Links
Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
Date:4/25/2011

MINNETONKA, Minn., April 25, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of clinical studies using Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products are scheduled to be presented at three upcoming professional meetings.  The meetings include the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Washington DC, May 1 - 4; the American Urological Association (AUA) Annual Meeting in Washington DC, May 14 -17; and the American Society of Colon & Rectal Surgeons (ASCRS) Annual Meeting in Vancouver, Canada, May 14 -18.  

"There is a growing body of clinical evidence in support of our Urgent PC and Macroplastique products," said David Kaysen, President and CEO of Uroplasty.  "This new data, along with previously published studies, confirms the efficacy and safety of both our products for the treatment of patients who suffer daily with overactive bladder or stress urinary incontinence."  

ACOG Presentations

  • Percutaneous Tibial Nerve Stimulation vs. Validated Sham in those Exposed to Pharmacologic Therapy presented by Dr. Denise Elser, Illinois Urogynecology, Oak Lawn, IL
  • Percutaneous Tibial Nerve Stimulation (PTNS) and the Effect on Fecal Incontinence* presented by Dr. Craig McCoy, Central Missouri Women's Healthcare, Marshall, MO

    • AUA Presentations

  • Insight into Percutaneous Tibial Nerve Stimulation: Critical Evaluation of the SUmiT Trial presented by Dr. Kenneth M. Peters, Beaumont Hospital, Royal Oak, MI
  • Long-term Durability of Polydimethylsiloxane Injection for Female Stress Urinary Incontinence Correlates with Hi
    '/>"/>

    • SOURCE Uroplasty, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3

    Related medicine technology :

    1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
    6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
    10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/20/2013)... , BERLIN and ... Arthroscopy Devices Market to 2018 ... Invasive Procedures to Drive Future Growth" looks at the ... six arthroscopy device market segments: arthroscopes, arthroscopy shavers, arthroscopy ... systems, and arthroscopy visualization systems. The report provides comprehensive ...
    (Date:5/20/2013)... 2013  Rhythm announced today the presentation of results ... of gastroparesis symptoms among diabetic patients in the U.S. ... among patients with both type 1 and type 2 ... with the more common type 2 disease. ... Associate Professor of Medicine at Harvard Medical School and ...
    (Date:5/20/2013)... May 20, 2013  AbbVie (NYSE: ... Phase 3 clinical study called SONAR (Study Of ... of the investigational compound atrasentan - when added to ... in patients with stage 2 to 4 chronic ... is a large, multinational, double-blind, placebo-controlled clinical study ...
    Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
    ... Inc. (Nasdaq: MAPP ) today announced that the ... Stifel Nicolaus Healthcare Conference Thursday, September 8, at ... Sciences Conference Wednesday, September 21, at 9:30 a.m. ET in ... will be available on the Investor Relations section of MAP ...
    ... THOUSAND OAKS, Calif., Sept. 6, 2011 Amgen (NASDAQ: ... on Thursday, Sept. 8, 2011, at The New York Palace ... Time. Arvind Sood, vice president of Investor Relations at Amgen, ... from the Events Calendar on Amgen,s website, www.amgen.com , ...
    Cached Medicine Technology:
    (Date:5/20/2013)... New York, NY (PRWEB) May 20, 2013 ... to protecting the rights of victims injured by defective ... South Dakota man who alleges that use of the ... The suit was filed on April 30, 2013, ... of Louisiana (Case No. 6:13-cv-0888), where it is one ...
    (Date:5/20/2013)... (PRWEB) May 20, 2013 Mirena ... in the multidistrict litigation recently established in U.S. District ... reports. According to court records, the litigation’s first ... time appointments to Plaintiff’s leadership positions were discussed. ... in the Southern District of New York, all of ...
    (Date:5/20/2013)... Salt Lake Community College’s Know Greater Heroes program ... winners for 2013. As part of the award, the ... is a leadership training program that involves SLCC athletes who ... eat right, be active, and avoid drugs and alcohol. , ... program each year, and visit more than 30 schools each ...
    (Date:5/20/2013)... The judge overseeing pretrial proceedings in ... specifically for female lawyers to be included in a ... Group LLP acknowledges the judge’s request, noting that its ... providing information on Mirena side effects and how to ... the addition of some female lawyers to the committee. ...
    (Date:5/20/2013)... 2013 While Huntington,s disease (HD) is currently ... disease-modifying therapies in development may slow or minimize ... depends upon the identification of reliable and sensitive ... these biomarkers may eventually be used as outcome ... helpful to monitor changes during the time prior ...
    Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3
    ... Cleaners Proven to Protect and Even Improve Health, ... homes is,increasingly contaminated and polluted, and now studies have ... not only allergy and asthma,symptoms but also a variety ... clots., Studies are emerging that prove poor indoor ...
    ... the type diagnosed in Sen. Edward Kennedy , , MONDAY, ... is showing promise against the same general type of ... reporting. , The vaccine, when given with chemotherapy, more ... tumors. Kennedy was diagnosed last month with a malignant ...
    ... The discovery of new genetic mutations involved in inflammatory ... these common conditions, two scientists told the annual conference ... 2 June). , Dr.Alexandra ... Netherlands, and Dr. Eleonora Festen, from the University of ...
    ... ST. PETERSBURG, Fla., June 2 The Advanced,Wound Management ... announced,today that its negative pressure wound therapy (NPWT) products ... areas included in the,first phase of the competitive bidding ... (CMS) in the U.S. The program, which is,scheduled to ...
    ... family of CCRCs with expansion into Alabama;,Community to ... June 2 ACTS Retirement-Life,Communities, a premier not-for-profit ... its acquisition of Carlton Cove, a,continuing care retirement ... renamed Magnolia Trace and become the 19th ACTS,continuing ...
    ... the body,s own tissues and organs, wreaking havoc and ... of these diseases are so obscure, no effective treatment ... Weizmann Institute scientists have developed a method that in ... diseases effectively without necessarily knowing their exact cause. Their ...
    Cached Medicine News:Health News:Studies Find Poor Indoor Air Quality Can Lead to Major Health Problems 2Health News:Studies Find Poor Indoor Air Quality Can Lead to Major Health Problems 3Health News:Vaccine May Boost Survival of Brain Cancer Patients 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 3Health News:Discovery of new family of genetic mutations involved in inflammatory intestinal disease 2Health News:Discovery of new family of genetic mutations involved in inflammatory intestinal disease 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 2Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 4Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 5Health News:ACTS Retirement-Life Communities Completes Carlton Cove Acquisition 2Health News:Weizmann Institute scientists develop a new approach to treating autoimmune disease 2
    ...
    Designed to minimize emblolic debris in SVGs and carotids...
    ... the ability of interventional cardiologists and ... disease, and provides non-interventional cardiologists with ... treatment of patients who have become ... provides a noninvasive, atraumatic treatment for ...
    ... petite titanium model comes with ... lumen) and is our smallest ... offer larger lumen equivalency while ... lumen offset-tip catheters are available ...
    Medicine Products: